-
Publication Venue For
-
Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
2019
-
Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine..
24:e103-e105.
2019
-
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma..
24:202-210.
2019
-
Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia..
24:247-254.
2019
-
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
2018
-
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
2018
-
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.
2018
-
Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)..
23:1016-1023.
2018
-
Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long-Term Childhood Cancer Survivors..
23:965-973.
2018
-
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma..
23:889-e98.
2018
-
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..
23:782-790.
2018
-
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
23:403-409.
2018
-
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval..
23:328-336.
2018
-
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma..
23:157-e21.
2018
-
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
2018
-
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer..
22:642-647.
2017
-
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer..
22:375-e30.
2017
-
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials..
22:189-198.
2017
-
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803..
22:107-114.
2017
-
A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?.
21:1157-1160.
2016
-
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial..
21:789-794.
2016
-
Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting..
21:731-738.
2016
-
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
21:141-149.
2016
-
Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies..
20:773-779.
2015
-
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma..
20:727-728.
2015
-
Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan..
20:532-538.
2015
-
Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop..
20:186-195.
2015
-
Patient Experience and Attitudes Toward Addressing the Cost of Breast Cancer Care.
19:1135-1140.
2014
-
Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients..
19:999-1005.
2014
-
Self-reported financial burden and satisfaction with care among patients with cancer..
19:414-420.
2014
-
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing..
19:235-242.
2014
-
Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop..
19:21-31.
2014
-
The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics.
18:221-231.
2013
-
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas..
18:271-272.
2013
-
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies..
18:273-280.
2013
-
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials..
18:1004-1012.
2013
-
Oncology comparative effectiveness research:Amultistakeholder perspective on principles for conduct and reporting.
18:760-767.
2013
-
The Role of Brachyury in Notochordal and Non-Notochordal Malignancy.
18:S1-S1.
2013
-
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience..
18:381-390.
2013
-
Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis..
18:1321-1329.
2013
-
A Pilot Randomized Controlled Trial of Brief Cognitive-Behavioral Therapy for Anxiety in Patients with Terminal Cancer.
17:1337-1345.
2012
-
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability..
17:9-10.
2012
-
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)..
17:937-946.
2012
-
Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer..
17:1551-1561.
2012
-
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer..
17:513-524.
2012
-
Changes in swallowing-related quality of life after parathyroidectomy for hyperparathyroidism: a prospective cohort study..
17:1271-1276.
2012
-
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer..
17:1496-1503.
2012
-
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study..
17:1486-1495.
2012
-
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer..
16:61-70.
2011
-
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer..
16:1131-1137.
2011
-
Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy..
16:1714-1720.
2011
-
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions..
16:1397-1402.
2011
-
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)..
15:1310-1319.
2010
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study..
15:1329-1334.
2010
-
Economic burden for informal caregivers of lung and colorectal cancer patients..
15:883-893.
2010
-
Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain..
15 Suppl 2:19-23.
2010
-
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature..
14:816-827.
2009
-
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer..
14:22-28.
2009
-
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer..
13:1021-1029.
2008
-
Malignancy after solid organ transplantation: an overview..
13:769-778.
2008
-
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer..
13:515-525.
2008
-
The ethical justification for minor sibling bone marrow donation: a case study..
13:148-151.
2008
-
Commentary: rectal cancer an evolution of treatment..
12:1319-1320.
2007
-
Extended resection for pancreatic adenocarcinoma..
12:654-663.
2007
-
Anal cancer: an overview..
12:524-534.
2007
-
Salvage therapy in Hodgkin's lymphoma..
12:156-167.
2007
-
Thymoma: benign appearance, malignant potential..
11:887-894.
2006
-
Hairy cell leukemia: An elusive but treatable disease.
11:780-789.
2006
-
Risk models for predicting chemotherapy-induced neutropenia..
10:427-437.
2005
-
New combinations in metastatic colorectal cancer: what are our expectations?.
10:320-322.
2005
-
Never too old? Age should not be a barrier to enrollment in cancer clinical trials..
10:198-204.
2005
-
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy..
10 Suppl 3:30-39.
2005
-
Introduction: Targeting angiogenesis in cancer therapy.
9:1.
2004
-
Conformal radiation therapy for childhood CNS tumors..
9:442-450.
2004
-
Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?.
9 Suppl 5:31-40.
2004
-
Targeted therapy of colorectal cancer: clinical experience with bevacizumab..
9 Suppl 1:11-18.
2004
-
rHuEPO and improved treatment outcomes: potential modes of action..
9 Suppl 5:41-47.
2004
-
Activation of tyrosine kinases in cancer..
8:531-538.
2003
-
Interpreting measures of treatment effect in cancer clinical trials..
7:181-187.
2002
-
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium..
6 Suppl 1:20-24.
2001
-
MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer..
5:108-114.
2000
-
Research and quality medicine in the community: The paradigm of marrow transplantation.
3:354-356.
1998
-
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
2016
-
Patient experience and attitudes toward addressing the cost of breast cancer care.
2014
-
Imaging Approaches in Oncology: Update on PET/CT
2012